BGM Associates
  • What we do
    • Our services
    • Our Focus
  • Who we are
    • People
    • Advisory Board
  • Our Thinking
  • News
  • Careers
  • Contact us
  • What we do
    • Our services
    • Our Focus
  • Who we are
    • People
    • Advisory Board
  • Our Thinking
  • News
  • Careers
  • Contact us

NEWS

News about our organization and our activities​​

BGM Associates and DuChemBio Korea establish a Licensing Consortium for Breast Cancer Imaging Agent with a Korean leading medical institution – Asan Medical Center

24/6/2018

 
PictureL to R: Friedrich W. Gause, Dr. Seung Jun Oh, Jong Woo Kim
During the 2018 annual meeting of the Society of Nuclear Medicine and Molecular Imaging in Philadelphia, representatives of Asan Medical Center, DuChemBio Co., Ltd. and BGM Associates GmbH inked a Licensing Consortium Agreement for the international partnering of the molecular imaging compound – [18F]-fluoroestradiol (FES). [18F]FES is a fluorine-18 labelled radiopharmaceutical used for the imaging of breast cancer patients with positron emission tomography (PET) cameras.
 
Asan Medical Center, one of the leading research hospitals in Asia-Pacific region, has recently finalized its phase III trial in Korea and is now seeking regulatory approval for the [18F]FES from Korean Health Authorities.
 
DuChemBio, the leading radiopharmaceutical company in Korea, alongside BGM Associates are now in charge of the international partnering and development of the breast cancer radiopharmaceutical.


Comments are closed.

    BGM News Blog

    We regularly publish news from within our firm and our focus industries

    News categories

    All
    Events
    Management & Personnel
    Projects
    Publications & Presentations

    View my profile on LinkedIn

CONNECT WITH US

info@bgmassociates.com
+49  30  8148  7127

VISIT OUR OFFICE

Winkler Straße 11
14193 Berlin – Germany

 

© COPYRIGHT 2012-2019. ALL RIGHTS RESERVED | ​TERMS OF USE | LEGAL NOTICE | PRIVACY POLICY